Advertisement

Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib

Published:December 02, 2022DOI:https://doi.org/10.1016/j.clgc.2022.11.021

      Abstract

      Introduction

      The long-term clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) and a complete response (CR) to the tyrosine kinase inhibitor (TKI) sunitinib are poorly known. The characteristics of these patients could reveal previously undetected associations with clinical variables.

      Patients and Methods

      This observational, retrospective study (ATILA) used data from a registry of patients with mRCC who had received first-line sunitinib and had achieved CR from 2007 to 2018 in Spain.

      Results

      Sixty-two patients with CR were included; 48 patients (77.4%) received sunitinib in monotherapy and 14 (22.6%) combined with or followed by local treatment. Median age was 58.5 years (range, 32–81). Most patients (79.0%) had clear cell histology and had undergone previous nephrectomy (90.3%). The majority (70.2%) had an intermediate IMDC prognosis, 23% favorable and 7.0% poor. The median time on treatment with sunitinib was 28.2 months (IQR, 16.7–41.0) and the median time to CR was 10.9 months (IQR, 7.2–19.3). After a median follow-up of 8 years (range, 3–13 years), the median PFS was not reached. The overall median duration of complete response was 64.1 months (IQR, 32.2–99.4). The tolerance and safety profile of sunitinib was consistent with previous reports.

      Conclusion

      Durable CR to sunitinib was observed in patients regardless the prognosis group, metastasis site or histology type, with 75% of patients remaining in CR after 10 years. Clinicaltrials.gov: NCT03916458.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • GLOBOCAN
        Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer.
        2020 (Accessed January 10, 2022. Published online)
        • Padala SA
        • Barsouk A
        • Thandra KC
        • et al.
        Epidemiology of Renal Cell Carcinoma.
        World J Oncol. 2020; 11: 79-87https://doi.org/10.14740/wjon1279
        • Escudier B
        • Porta C
        • Schmidinger M
        • et al.
        Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2019; 30: 706-720https://doi.org/10.1093/annonc/mdz056
        • Motzer RJ
        • Penkov K
        • Haanen J
        • et al.
        Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.
        N Engl J Med. 2019; 380: 1103-1115https://doi.org/10.1056/NEJMoa1816047
      1. Ljungberg B, Albiges L, Bedke J, et al. European Association of Urology guidelines on renal cell carcinoma, 2021 update. https://uroweb.org/guideline/renal-cell-carcinoma/. Accessed January 2022. Published online 2021.

      2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines)—Kidney Cancer—Version 1.2022—July 1, 2021. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1440. Accessed January 2022. Published online 2021.

        • de Velasco G
        • Bex A
        • Albiges L
        • et al.
        Sequencing and combination of systemic therapy in metastatic renal cell carcinoma.
        Eur Urol Oncol. 2019; 2: 505-514https://doi.org/10.1016/j.euo.2019.06.022
        • Khan Y
        • Slattery TD
        • Pickering LM.
        Individualizing systemic therapies in first line treatment and beyond for advanced renal cell carcinoma.
        Cancers (Basel). 2020; 12: E3750https://doi.org/10.3390/cancers12123750
        • Motzer RJ
        • Escudier B
        • Gannon A
        • Figlin RA.
        Sunitinib: ten years of successful clinical use and study in advanced renal cell carcinoma.
        The Oncol. 2017; 22: 41-52https://doi.org/10.1634/theoncologist.2016-0197
        • Moran M
        • Nickens D
        • Adcock K
        • et al.
        Sunitinib for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world and clinical trials data.
        Target Oncol. 2019; 14: 405-416https://doi.org/10.1007/s11523-019-00653-5
        • Motzer RJ
        • Tannir NM
        • McDermott DF
        • et al.
        Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.
        N Engl J Med. 2018; 378: 1277-1290https://doi.org/10.1056/NEJMoa1712126
        • Rini BI
        • Plimack ER
        • Stus V
        • et al.
        Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.
        N Engl J Med. 2019; 380: 1116-1127https://doi.org/10.1056/NEJMoa1816714
        • Choueiri TK
        • Powles T
        • Burotto M
        • et al.
        Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma.
        N Engl J Med. 2021; 384: 829-841https://doi.org/10.1056/NEJMoa2026982
        • Savard MF
        • Wells JC
        • Graham J
        • et al.
        Real-world assessment of clinical outcomes among first-line sunitinib patients with clear cell metastatic renal cell carcinoma (mRCC) by the International mRCC database consortium risk group.
        Oncologist. 2020; 25: 422-430https://doi.org/10.1634/theoncologist.2019-0605
        • Molina AM
        • Jia X
        • Feldman DR
        • et al.
        Long-term response to sunitinib therapy for metastatic renal cell carcinoma.
        Clin Genitourin Cancer. 2013; 11: 297-302https://doi.org/10.1016/j.clgc.2013.04.001
        • Porta C
        • Gore ME
        • Rini BI
        • et al.
        Long-term safety of sunitinib in metastatic renal cell carcinoma.
        European Urology. 2016; 69: 345-351https://doi.org/10.1016/j.eururo.2015.07.006
        • Puente J
        • Laínez N
        • Dueñas M
        • et al.
        Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma.
        Oncotarget. 2017; 8: 30410-30421https://doi.org/10.18632/oncotarget.16494
        • Schmidinger M
        • Porta C
        • Oudard S
        • et al.
        Real-world experience with sunitinib treatment in patients with metastatic renal cell carcinoma: clinical outcome according to risk score.
        Clin Genitourin Cancer. 2020; 18: e588-e597https://doi.org/10.1016/j.clgc.2020.02.013
        • Motzer RJ
        • Bukowski RM
        • Szczylik C
        • Baum CM.
        Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
        N Engl J Med. 2007; (Published online): 10
        • Motzer RJ
        • Hutson TE
        • Tomczak P
        • et al.
        Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
        JCO. 2009; 27: 3584-3590https://doi.org/10.1200/JCO.2008.20.1293
        • Gore ME
        • Szczylik C
        • Porta C
        • et al.
        Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.
        Br J Cancer. 2015; 113: 12-19https://doi.org/10.1038/bjc.2015.196
        • Iacovelli R
        • Alesini D
        • Palazzo A
        • et al.
        Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.
        Cancer Treatment Reviews. 2014; 40: 271-275https://doi.org/10.1016/j.ctrv.2013.09.003
        • Buchler T
        • Bortlicek Z
        • Poprach A
        • et al.
        Outcomes for patients with metastatic renal cell carcinoma achieving a complete response on targeted therapy: a registry-based analysis.
        European Urology. 2016; 70: 469-475https://doi.org/10.1016/j.eururo.2015.12.031
        • Albiges L
        • Oudard S
        • Negrier S
        • et al.
        Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.
        JCO. 2012; 30: 482-487https://doi.org/10.1200/JCO.2011.37.2516
        • Zambrana F
        • Carril-Ajuria L
        • Gómez de Liaño A
        • et al.
        Complete response and renal cell carcinoma in the immunotherapy era: the paradox of good news.
        Cancer Treat Rev. 2021; 99102239https://doi.org/10.1016/j.ctrv.2021.102239
        • Johannsen M
        • Staehler M
        • Ohlmann CH
        • et al.
        Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy.
        Annals of Oncology. 2011; 22: 657-663https://doi.org/10.1093/annonc/mdq437
        • Hutson TE
        • Bukowski RM
        • Rini BI
        • et al.
        Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.
        Br J Cancer. 2014; 110: 1125-1132https://doi.org/10.1038/bjc.2013.832
        • Neuzillet Y
        • Albrand G
        • Caillet P
        • Paillaud E
        • Mongiat-Artus P.
        [Specificity of the management of metastatic renal cancer in the older patient].
        Prog Urol. 2019; 29: 874-895https://doi.org/10.1016/j.purol.2019.08.272
        • McDermott DF
        • Huseni MA
        • Atkins MB
        • et al.
        Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
        Nat Med. 2018; 24: 749-757https://doi.org/10.1038/s41591-018-0053-3
        • Motzer RJ
        • Banchereau R
        • Hamidi H
        • et al.
        Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade.
        Cancer Cell. 2020; 38: 803-817.e4https://doi.org/10.1016/j.ccell.2020.10.011
        • Motzer RJ
        • Choueiri TK
        • McDermott DF
        • et al.
        Biomarker analysis from checkmate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma.
        J Immunother Cancer. 2022; 10e004316https://doi.org/10.1136/jitc-2021-004316
        • Manneh R
        • Lema M
        • Carril-Ajuria L
        • et al.
        Immune checkpoint inhibitor combination therapy versus sunitinib as first-line treatment for favorable-IMDC-risk advanced renal cell carcinoma patients: a meta-analysis of randomized clinical trials.
        Biomedicines. 2022; 10: 577https://doi.org/10.3390/biomedicines10030577
        • Metcalf MR
        • Peña VN
        • Cheaib JG
        • Srivastava A
        • Pierorazio PM
        • Patel HD.
        Disparities in the treatment and survival of metastatic renal cell carcinoma.
        Urology. 2021; (Published online November 19S0090-4295(21)01069-4)https://doi.org/10.1016/j.urology.2021.08.070
        • Vano YA
        • Ladoire S
        • Elaidi R
        • et al.
        First-line treatment of metastatic clear cell renal cell carcinoma: what are the most appropriate combination therapies?.
        Cancers (Basel). 2021; 13: 5548https://doi.org/10.3390/cancers13215548
        • Shah AY
        • Kotecha RR
        • Lemke EA
        • et al.
        Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
        European Journal of Cancer. 2019; 114: 67-75https://doi.org/10.1016/j.ejca.2019.04.003
        • Rossi E
        • Bersanelli M
        • Gelibter AJ
        • et al.
        Combination therapy in renal cell carcinoma: the best choice for every patient?.
        Curr Oncol Rep. 2021; 23: 147https://doi.org/10.1007/s11912-021-01140-9
        • Fontes-Sousa M
        • Magalhães H
        • Oliveira A
        • et al.
        Reviewing treatment options for advanced renal cell carcinoma: is there still a place for tyrosine kinase inhibitor (TKI) monotherapy?.
        Adv Ther. 2022; (Jan 13): 1-19https://doi.org/10.1007/s12325-021-02007-y